Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206154 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT00206154: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00206154 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206154, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Interventions
- DRUG Formoterol Turbuhaler
- DRUG Budesonide/formoterol pMDI
- DRUG Budesonide pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
What the finished NCT00206154 record still lists
NCT00206154 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher).
The record links to 0 conditions, and to 3 interventions - of which Formoterol Turbuhaler is the first listed.
NCT00206154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206154 about?
NCT00206154 is a clinical study titled "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients". The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT00206154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2005-04. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00206154?
The interventions under investigation include: Formoterol Turbuhaler (DRUG), Budesonide/formoterol pMDI (DRUG), Budesonide pMDI (DRUG).
Who is sponsoring clinical trial NCT00206154?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206154's enrollment target sits among peer trials
1,500 158th of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia